Li Jun International (01355.HK) Hot Stock Analysis Report

This analysis is based on market events at 16:30:01 UTC+8 on January 5, 2026. Market attention on Li Jun International (01355.HK) mainly stems from the continued impact of its acquisition and renaming plan announced on December 23, 2025.

1. Stock Overview
   : Li Jun International (01355.HK) intends to rename itself “Biosystems Engineering Co., Ltd.” and belongs to the Healthcare/Biotechnology sector. As of December 31, 2025, its share price was HK$0.125 with a market capitalization of approximately HK$149 million [3].
2. Reasons for Popularity
   : On December 23, 2025, the company announced the acquisition of 100% equity of Aonuo Hong Kong for HK$22 million, indirectly obtaining a 37.5% stake in Baisheng Biology. Baisheng Biology is a synthetic biology infrastructure provider with complete R&D and production capabilities. The simultaneous intention to rename clearly signals a strategic shift to the popular synthetic biology field, attracting investor attention [1][2].
3. Price and Volume
   : As of December 31, 2025, the 52-week price range was HK$0.064-HK$0.238. Due to its small market capitalization (approximately HK$149 million), liquidity is weak, and the latest turnover rate and volume data are insufficient; subsequent performance needs to be monitored [3].
4. Market Sentiment
   : Positive sentiment is driven by the popularity of the synthetic biology sector, expectations of strategic transformation, and the technical capabilities of the acquisition target; however, factors such as weak fundamentals (interim losses), susceptibility to speculation due to small market capitalization, and pending acquisition completion suppress sentiment, leading to an overall mixed stance [4][3].

1. Resonance between Sector Popularity and Strategic Transformation
   : As a global biotech hot sector, synthetic biology aligns perfectly with the company’s transformation moves, becoming the main driver of short-term stock price fluctuations.
2. Speculative Nature of Small-Cap Companies
   : With a market capitalization of approximately HK$149 million, it is vulnerable to short-term speculative funds, and stock price trends may deviate from fundamentals; investors need to be alert to volatility risks.
3. Contrast Between Fundamentals and Transformation Expectations
   : The company recorded an interim loss of HK$13.484 million, with negative P/E and P/B ratios, and poor financial conditions; there is uncertainty about whether transformation can improve fundamentals [4].

1. Fundamental Risk
   : As of June 30, 2025, the interim loss attributable to shareholders was HK$13.484 million, with weak financial conditions [4];
2. Liquidity Risk
   : Small market capitalization leads to insufficient liquidity, prone to large price fluctuations [3];
3. Acquisition Uncertainty
   : The acquisition is in the proposed stage, with completion time and effects to be verified [1];
4. Speculative Risk
   : Stock prices are susceptible to short-term funds, and trends may deviate from fundamentals [3].

1. Synthetic Biology Sector Potential
   : With high global attention in this field, the company may benefit from industry development if transformation succeeds [1][2];
2. Technology Reserve Expectations
   : Baisheng Biology’s synthetic biology R&D and production capabilities provide technical support for the company’s future development [1].

Li Jun International (01355.HK) has become a market hot spot due to its acquisition of a synthetic biology company and proposed strategic transformation. Although the synthetic biology sector has development potential, the company faces risks such as weak fundamentals, insufficient liquidity, and acquisition uncertainty. Investors should monitor subsequent acquisition progress, company transformation implementation, and industry dynamics, and make decisions based on their own risk preferences.

[1] Sina Finance Report [1]
[2] AASTOCKS Report [2]
[3] Xueqiu Market Data [3]
[4] Sina Finance Financial Report [4]